Biofidelity: Robert Osborne

Dec 10, 2020

Biofidelity has appointed Robert Osborne as its chief operating officer. Osborne previously served as senior VP of technology and assay development at Inivata. Prior to Inivata, Osborne served as principal staff scientist at the Wellcome Trust Sanger Institute, director of technology development at its spinout company, 14M Genomics, and director of research at Population Genetics Technologies.

Breaking News

SARS-CoV-2 Variants of Concerns Evolved to Modify Host Immune Response, Multiomics Study Shows
People in the News at GA4GH, Mercy BioAnalytics, Deepcell, One Biosciences
New Products Posted to GenomeWeb: Clinical Microbiomics, Integra Biosciences, DNAstack, Bruker
Angolan Namib Desert Population Analysis Uncovers New Ancestry Group With Deep Divergence
Cedars-Sinai Sets Up $25M Single Cell Precision Medicine Center

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.